Thus, NK-92 cell line is a potential effective immunotherapy tool for CD56-positive breast cancer treatment and induction of CD56 expression combined with NK-92-adoptive transfer might become a novel attractive approach for sensitizing initially resistant CD56-negative breast tumors. Here, NCAM1 is linked to breast neoplasm.